We are very pleased to announce that Polyplus-transfection® SA, has trusted In Vitro Technologies as their new exclusive distributor in Australia and New Zealand.
Located close to the University of Strasbourg in France, Polyplus-transfection® SA is a biotechnology company that develops and sells innovative, high efficiency transfection reagents for the delivery of nucleic acids in research, bioproduction and therapeutics.
We are very pleased to announce that Terumo BCT has appointed In Vitro Technologies as their new distributor in Australia and New Zealand effective 1 June 2018, supporting the Cell Therapy Technologies range of products.
ATCC's toxicological tools can also be used to identify responses to environmental insults or to screen pharmaceutical compounds. These cells are applicable for bench work and large-scale screening and are fully characterized and functionally tested.
ATCC has updated the White Paper Synthetic Nucleic Acids for the Development and Evaluation of In Vitro Diagnostic Devices Designed to Detect Dengue, Chikungunya, and Zika White Paper.
To support Australian and New Zealand research in the fight against cancer, In Vitro Technologies offered 5 Travel Grants to Australian and New Zealand researchers to attend the Eradicate Cancer Conference in Melbourne in March 2018. And the winners are...
Great publication about improving the efficacy of adoptive T-Cell therapy in solid tumours by using 3rd generation CAR-T cells.
Scientists at the University of Oxford have described a new twist on cancer immunotherapy, combining two independent cell killing approaches in a single therapeutic with high potency and broad applicability.
In Vitro Technologies would like to congratulate Dr. Andreas Behren and the Cancer Immunobiology team at the Olivia Newton-John Cancer Research (ONJCRI) Institute in Melbourne for winning the Advanced Cell Diagnostics $40,000 USD research grant.
In Vitro Technologies are proud to work closely with the new NSW Health Statewide Biobank, the largest biobank in the southern hemisphere.
In the latest vote of confidence that cellular immunotherapy is going to live up to its potential for transforming the way cancer is treated, this week Gilead Sciences purchased Kite Pharma, a leader in the development of chimeric antigen receptor (CAR) T cells, for $11.9 billion dollars.
